Kyverna Therapeutics Inc. (KYTX) stock has reached a new 52-week low, trading at $2.78, down 10.4% in the past week alone, as the biotechnology firm faces a challenging market environment. According ...

The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the expansion of SELVA, its Phase 3 clinical trial of ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now locked in another big biotech deal.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palvella Therapeutics (PVLA – Research Report) ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Kyverna Therapeutics, Inc. (KYTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

New York, New York-- (Newsfile Corp. - February 7, 2025) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ...